Bioprocessing Trends – Demonstrating Bioprocessing Comparability In The Modern Analytical Age

By Jeffrey Mocny, VP of Regulatory Strategy

Manufacturing changes are inevitable across the lifecycle of a biologic, from facility transfers and equipment upgrades to restarting paused programs. While modern bioprocessing offers greater control over product quality, even well‑intended changes can alter critical quality attributes and introduce risk. Demonstrating comparability is therefore essential to protect patient safety, preserve prior clinical data, and meet regulatory expectations.

A successful comparability strategy starts with building a deep understanding of both the molecule and the original process before assessing risk or selecting analytical methods. This includes clearly defining CQAs, CPPs, therapeutic windows, and process controls, then evaluating how proposed changes could affect manufacturability, safety, or efficacy. Risk‑based analytical approaches help determine where deeper characterization or additional studies may be required.

By taking a holistic, data‑driven approach to comparability—rather than relying solely on specifications—development teams can reduce uncertainty, avoid unnecessary clinical work, and confidently implement process changes while maintaining regulatory confidence and long‑term product viability.